Drug Trial Radar · NCT00650624
A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)
Last checked: Nov 20, 2026Latest source record: Dec 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
416
Actual
Start
Jun 2003
Primary completion
Not stated
Study completion Jan 2004
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 2, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the therapeutic dose range of valdecoxib by comparing the efficacy of three dosing regimens (5 mg, 10 mg and 20 mg once daily) with placebo for relief of the signs and symptoms of osteoarthritis of the knee. To assess safety and tolerability of multiple doses of valdecoxib in patients with osteoarthritis of the knee.
Conditions
- Osteoarthritis, Knee
Interventions
valdecoxibDrug
valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
valdecoxibDrug
valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
valdecoxibDrug
valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
placeboDrug
placebo tablet by mouth once daily in the morning for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- WOMAC (Western Ontario and McMaster Universities) OA Pain IndexTime frame: screening (Day -14), baseline (week 0), and at weeks 2, 4, and 6 (final visit)
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Saga, Japan
Pfizer Investigational Site
Tokyo, Japan
Pfizer Investigational Site
Funabashi, Chiba, Japan
Pfizer Investigational Site
Sakura, Chiba, Japan
Pfizer Investigational Site
Chikushi-gun, Fukuoka, Japan
Pfizer Investigational Site
Iizuka, Fukuoka, Japan
Pfizer Investigational Site
Kurume, Fukuoka, Japan
Pfizer Investigational Site
Yame, Fukuoka, Japan
Pfizer Investigational Site
Chitose, Hokkaido, Japan
Pfizer Investigational Site
Sapporo, Hokkaido, Japan
Pfizer Investigational Site
Kamakura, Kanagawa, Japan
Pfizer Investigational Site
Yokohama, Kanagawa, Japan
Pfizer Investigational Site
Isahaya, Nagasaki, Japan
Pfizer Investigational Site
Hirakata, Osaka, Japan
Pfizer Investigational Site
Kanzaki-gun, Saga-ken, Japan
Pfizer Investigational Site
Karatsu, Saga-ken, Japan
Pfizer Investigational Site
Ogi-gun, Saga-ken, Japan
Pfizer Investigational Site
Setagaya-ku, Tokyo, Japan
Pfizer Investigational Site
Shinjuku-Ku, Tokyo, Japan
Pfizer Investigational Site
tabashi City, Tokyo, Japan
Pfizer Investigational Site
Taito-ku, Tokyo, Japan
Pfizer Investigational Site
Yoyogi Shibuya-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.